Cerus Co. (NASDAQ:CERS) Insider Laurence M. Corash Acquires 150,011 Shares

Cerus Co. (NASDAQ:CERS) insider Laurence M. Corash purchased 150,011 shares of the firm’s stock in a transaction on Thursday, March 15th. The stock was acquired at an average price of $5.15 per share, with a total value of $772,556.65. Following the completion of the purchase, the insider now owns 1,462,580 shares of the company’s stock, valued at approximately $7,532,287. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

NASDAQ:CERS traded down $0.10 on Friday, reaching $5.20. The company’s stock had a trading volume of 1,198,090 shares, compared to its average volume of 1,448,325. Cerus Co. has a 12-month low of $1.93 and a 12-month high of $5.85. The company has a quick ratio of 3.26, a current ratio of 3.89 and a debt-to-equity ratio of 0.77. The company has a market capitalization of $673.90, a P/E ratio of -9.29 and a beta of 1.75.

How to Become a New Pot Stock Millionaire

Cerus (NASDAQ:CERS) last posted its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.01. The firm had revenue of $16.20 million for the quarter, compared to the consensus estimate of $17.53 million. Cerus had a negative return on equity of 154.46% and a negative net margin of 139.06%. The company’s quarterly revenue was up 60.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.13) EPS. sell-side analysts anticipate that Cerus Co. will post -0.43 earnings per share for the current fiscal year.

CERS has been the subject of several research analyst reports. Cantor Fitzgerald reissued a “buy” rating and issued a $5.00 price objective on shares of Cerus in a report on Tuesday, January 23rd. Zacks Investment Research lowered Cerus from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. BTIG Research reissued a “hold” rating on shares of Cerus in a report on Thursday, January 25th. BidaskClub lowered Cerus from a “hold” rating to a “sell” rating in a report on Tuesday, December 12th. Finally, ValuEngine raised Cerus from a “strong sell” rating to a “sell” rating in a report on Thursday, January 4th. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $5.40.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BB&T Securities LLC acquired a new position in shares of Cerus during the 3rd quarter worth about $100,000. Teacher Retirement System of Texas acquired a new position in shares of Cerus during the 4th quarter worth about $126,000. MetLife Investment Advisors LLC acquired a new position in shares of Cerus during the 4th quarter worth about $197,000. Voya Investment Management LLC boosted its position in shares of Cerus by 22.0% during the 2nd quarter. Voya Investment Management LLC now owns 58,633 shares of the biotechnology company’s stock worth $147,000 after acquiring an additional 10,570 shares in the last quarter. Finally, Turner Investments LLC acquired a new position in shares of Cerus during the 3rd quarter worth about $177,000. 51.95% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/08/laurence-m-corash-buys-150011-shares-of-cerus-co-cers-stock.html.

About Cerus

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply